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Abstract
Background—Cytomegalovirus (CMV) infection can be acquired in utero or postnatally 
through horizontal transmission and breastfeeding. The effect of postnatal CMV infection on 
postnatal HIV transmission is unknown.
Methods—The Breastfeeding, Antiretrovirals and Nutrition study, conducted in Malawi, 
randomized 2369 mothers and their infants to three antiretroviral prophylaxis arms –mother (triple 
regimen), infant (nevirapine), or neither – for 28 weeks of breastfeeding, followed by weaning. 
Stored plasma and peripheral blood mononuclear cell specimens were available for 492 infants at 
24 weeks and were tested with CMV PCR. Available samples from infants who were CMV PCR-
positive at 24 weeks were also tested at birth (N = 242), and from infants PCR-negative at 24 
weeks were tested at 48 weeks (N = 96). Cox proportional-hazards models were used to determine 
if CMV infection was associated with infant morbidity, mortality, or postnatal HIV acquisition.
Results—At 24 weeks of age, CMV DNA was detected in 345/492 infants (70.1%); the 
estimated congenital CMV infection rate was 2.3%, and the estimated rate of CMV infection at 48 
weeks was 78.5%. CMV infection at 24 weeks was associated with subsequent HIV acquisition 
through breastfeeding or infant death between 24 and 48 weeks of age (hazard ratio 4.27, P = 
0.05).
Conclusion—Most breastfed infants of HIV-infected mothers in this resource-limited setting are 
infected with CMV by 24 weeks of age. Early CMV infection may be a risk factor for subsequent 
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infant HIV infection through breastfeeding, pointing to the need for comprehensive approaches in 
order to achieve elimination of breastfeeding transmission of HIV.
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Introduction
Congenital cytomegalovirus (CMV) infection – a result of intrauterine mother-to-infant 
transmission – is the most common congenital infection [1,2]. Postnatal acquisition of CMV 
can occur through horizontal transmission and through breastfeeding [3], and is thought to 
be generally benign in healthy full-term infants. However, premature infants or other groups 
of immuno-compromised infants are at risk for more extensive disease [4,5], and may also 
experience long-term cognitive delays [6].
Sub-Saharan Africa remains the region of the world most heavily affected by HIV-1; more 
than 90% of all children who acquired HIV-1 in 2011 resided in the sub-Saharan Africa. The 
interaction of CMV infection and HIV-1 transmission to the infant is complex and poorly 
understood. Studies have suggested that mother-to-child HIV transmission is more frequent 
among newborns with congenital CMV infection, and that infants with both infections 
experience higher rates of HIV disease progression, neurodevelopmental deficits, and death 
[7–11]. The effect of CMV infection on infants who are HIV-1-exposed but not infected has 
also received recent attention. In areas with high HIV-1 prevalence, there is some evidence 
that HIV-1-exposed but uninfected infants may be a population at risk for increased 
morbidity and mortality [12,13], decreased growth and psychomotor development [6], and 
immunologic abnormalities [14]. Whether postnatal CMV infection of the infant correlates 
with transmission of HIV-1 infection through breastfeeding has not, to our knowledge, been 
studied. Furthermore, whether maternal receipt of HAART may affect CMV transmission to 
the infant is unclear. The introduction of HAART in HIV-1-infected pregnant women has 
been associated with decreased rates of congenital and early postnatal CMV infection 
[15,16]. The role of postnatal HAART in reducing CMV transmission has not been 
evaluated to date.
The objectives of this study were: to delineate the relationship of congenital and postnatal 
CMV and HIV transmission in a cohort of infants born to HIV-1-infected mothers; to 
characterize any effects of CMV infection on the health and growth of these infants; and to 
determine whether HAART administered to the mothers during breastfeeding affected 
postnatal CMV transmission to the infants. We used samples collected and stored from 
infants enrolled in the Breastfeeding, Antiretrovirals and Nutrition (BAN) study [17], who 
breastfed for 28 weeks and were followed for their first 48 weeks of life in Lilongwe, 
Malawi.
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Study population and testing strategy
The BAN study was a randomized, controlled clinical trial that evaluated, in a factorial 
design, the safety and efficacy of: antiretroviral prophylaxis (maternal triple-drug 
antiretroviral regimen vs. infant daily nevirapine administered during 28 weeks of 
breastfeeding vs. a control arm of only one week of antiretroviral prophylaxis after 
delivery); and a maternal nutritional supplement during breastfeeding, in reducing postnatal 
mother-to-child HIV-1 transmission and in enhancing maternal health during breastfeeding 
[17]. The study randomized and followed 2369 mother–infant pairs between 2004 and 2010 
in Lilongwe, Malawi; enrolled infants had to have a birth weight of at least 2000 g and be 
HIV-uninfected by 2 weeks of age.
Information on the cumulative risk of HIV transmission, infant death, and serious morbidity 
outcomes, as well as anthropometric data, was available for all study infants. We used stored 
infant plasma and peripheral blood mononuclear cell (PBMC) specimens from birth, 24 
weeks, and 48 weeks of age, in order to detect congenital, early postnatal, and late postnatal 
CMV infection, respectively. Both stored plasma and PBMC specimens were available for 
492 infants at 24 weeks and were tested with CMV PCR. Available samples from infants 
who were positive by PCR at 24 weeks were also tested at birth (N = 242) to determine the 
congenital CMV infection rate. Available samples from those infants who were CMV PCR-
negative at 24 weeks were tested at 48 weeks (N = 96). An additional set of specimens from 
30 of the 119 infants who were HIV PCR-positive by 2 weeks of age (and excluded from 
further follow-up in the BAN study) was also tested, to derive the congenital CMV infection 
rate among infants HIV-infected in utero/intrapartum. This study was approved by the 
Institutional Review Boards of the University of North Carolina at Chapel Hill and by the 
Centers for Disease Control and Prevention.
Cytomegalovirus PCR
Total DNA was purified from plasma and PBMC specimens using Qiagen blood mini kits 
on the Qiacube automated DNA extractor (Qiagen, Valencia, California, USA). CMV load 
was measured by Taqman-based PCR using Perfecta Fastmix (Quanta Biosciences Inc., 
Gaithersburg, Maryland, USA) with amplification using the MX 3005P Real-time PCR 
System (Agilent Technologies, New Castle, Delaware, USA). PCR targeted the highly 
conserved viral immediate early 2 gene as described by Boppana et al. [18].
Statistical analysis
The rate of CMV infection as measured by CMV PCR and median CMV viral load was 
calculated at birth, 24 weeks, and 48 weeks, and separately by antiretroviral treatment group 
and infant HIV infection. To estimate the CMV infection rate at birth, all infants with a 
negative CMV PCR result at 24 weeks were assumed to also be negative at birth. To 
estimate the CMV infection rate at 48 weeks, all infants with a positive CMV PCR result at 
24 weeks were assumed to also be positive at 48 weeks. The estimated infection rates at 
birth and 48 weeks were adjusted for missing data by multiplying the number with assumed 
results by the percentage of those with available specimens.
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Rates of CMV infection were compared between groups using chi-square or Fisher’s exact 
test, and viral loads were compared using Wilcoxon rank-sum tests. Relative risks were 
calculated to examine the effect of potential predictors of CMV infection at 24 weeks, 
including maternal age, CD4+ T-cell count, maternal HIV load, infant birth weight, and 
infant white blood cell count at birth. To examine the effect of CMV infection on negative 
health outcomes in HIV-exposed infants, we included CMV PCR at 24 weeks as a covariate 
in mixed-effects models for infant growth and in Cox proportional-hazards regression 
models for serious infant morbidity requiring hospitalization (including severe pneumonia or 
serious febrile illness, severe diarrhea or growth faltering, and malaria), mortality, and HIV 
acquisition through breastfeeding (after 2 weeks of age). Results were considered 
statistically significant when P was less than 0.05.
Results
Only 492 of the 2369 infants enrolled in the BAN study had available stored plasma and 
PBMC specimens at 24 weeks of age and were tested for CMV. To ensure this subset was 
representative of the entire BAN study, demographic variables, maternal CD4+ cell count, 
infant characteristics at delivery, and infant HIV infection through breastfeeding were 
compared between the subset and all other infants without available specimens. No 
significant differences were found.
Detection of cytomegalovirus DNA in the infants
At 24 weeks of age, CMV DNA (either in plasma or in PBMC) was detected in 345 of 492 
infants [70.1%; 95% confidence interval (CI) 65.9%, 74.1%]. The median CMV plasma 
viral load at 24 weeks of age was 176.4 copies/ml [interquartile range (IQR) 88.6–433.3]. Of 
the CMV PCR-positive infants at 24 weeks and with available specimens at birth (n = 242), 
eight were also CMV PCR-positive at birth, with an estimated congenital CMV infection 
rate (as detected by positive plasma or PBMC CMV PCR) of 2.3% (95% CI 1.0%, 4.5%) 
(adjusted for missing data). All eight cases of congenital CMV infection were among infants 
who remained HIV-uninfected until their last study visit (six of eight completed 48 weeks). 
Of those CMV PCR-negative at 24 weeks with available specimens at 48 weeks, 27 of 96 
(28.1%) were CMV PCR-positive at 48 weeks of age, for an estimated cumulative rate of 
CMV infection (as detected by plasma/PBMC PCR) of 78.5% (95% CI 73.6%, 82.9%) at 48 
weeks (adjusted for missing data). The median CMV plasma viral load was 197.8 copies/ml 
(IQR 89.3–843.2) at birth and 61.3 copies/ml (IQR 30.7–111.7) at 48 weeks. The median 
CMV plasma viral load at 48 weeks was significantly lower than the respective values at 
birth (P = 0.02) and 24 weeks (P < 0.001).
An additional 30 birth specimens from infants HIV-PCR-positive at birth (n = 29) or at 1 
week of age (n = 1) (who were not further followed in the BAN study and thus not included 
in the above group) were tested by CMV PCR at birth. We found that three (10.0%; 95% CI 
2.1%, 26.5%) of these specimens were also positive by CMV PCR, which is significantly 
higher than the estimated 2.3% congenital CMV infection rate in the HIV-exposed 
uninfected infants (P = 0.049).
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Predictors of cytomegalovirus DNA detection and cytomegalovirus viral load levels at 24 
weeks
Infants with detectable CMV DNA at 24 weeks had mothers with lower antenatal CD4+ T-
cell count [relative risk (RR) = 0.95 for each 100 cell/μl increase; P = 0.002], higher HIV 
viral load during pregnancy (RR = 1.27 for each 1 unit increase in log10 viral load; P < 
0.0001), and had lower birth weight (RR = 0.99 for each 100 g increase; P = 0.047). The 
prevalence of infants with detectable CMV DNA at 24 weeks was similar for each study arm 
(70.2, 68.5, and 73.3% for the maternal antiretroviral, infant antiretroviral, and no-extended 
antiretroviral arm, respectively).
Cytomegalovirus plasma viral load was significantly higher in infants postnatally HIV-
infected by 24 weeks, compared to infants HIV-uninfected at 24 weeks (median 1258.6 vs. 
174.2 copies/ml; P = 0.045). For infants HIV-uninfected at 24 weeks, CMV viral load was 
higher in those who became HIV-infected by 48 weeks compared to those who remained 
HIV-uninfected at 48 weeks, but not significantly so (median 380.1 vs. 172.0 copies/ml; P = 
0.095).
Association of cytomegalovirus DNA detection at 24 weeks with HIV acquisition through 
breastfeeding and with infant morbidity, mortality, and growth
Among nine infants who became HIV-infected between 24 and 48 weeks of age, the 
prevalence of CMV DNAemia at 24 weeks of age was 88.9%, as compared with a 
prevalence of 69.8% among 476 who remained HIV-uninfected (P = 0.29), and a prevalence 
of 66.7% among six infants who became HIV-infected between 2 and 24 weeks of age (P = 
0.53). CMV DNAemia at 24 weeks showed a nonsignificant association with subsequent 
acquisition of HIV infection between 24 and 48 weeks (hazard ratio 4.52, P = 0.15), with 
infant mortality by 48 weeks of age (hazard ratio 4.05, P = 0.18) and with the combined 
measure of HIV infection or infant death between 2 and 24 weeks of age (hazard ratio 2.49, 
P = 0.09) (Table 1). A significant association was observed when the outcomes of HIV 
infection and infant death were combined between 24 and 48 weeks of age (hazard ratio 
4.27, P = 0.05). Kaplan–Meier estimates of the cumulative risk of HIV infection or death 
between 24 and 48 weeks of age by CMV DNAemia at 24 weeks are depicted in Fig. 1 (log-
rank P = 0.03).
Cytomegalovirus DNAemia was not associated with severe morbidity outcomes requiring 
hospitalization, or with decreased infant weight-for-age or length-for-age (Table 1).
Discussion
To our knowledge, this is the first study to date to specifically examine the relationship 
between CMV infection in HIV-exposed infants and postnatal transmission of HIV through 
breastfeeding, and to investigate the relationship between postnatal antiretroviral treatment 
and postnatal CMV acquisition. Our study shows that the majority of infants born to HIV-
infected mothers in a resource-limited setting practicing breastfeeding acquire CMV 
infection rapidly in their first year of life (70.1% by 24 weeks, 78.5% by 48 weeks). The 
estimated congenital CMV infection rate in infants HIV-uninfected at birth (as determined 
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by DNA PCR of plasma/PBMC) was 2.3%; in contrast, infants who were HIV-infected at 
birth had a congenital CMV infection rate of 10%.
Past studies have shown similar high rates of CMV infection in HIV-exposed uninfected 
infants living in resource-limited settings [6,19], and have also suggested that the rate of 
congenital CMV infection may also be higher in these populations. A recent study found a 
congenital CMV rate of 3.8% in neonates admitted to a large referral center in sub-Saharan 
Africa (by CMV PCR of serum, urine, and saliva), with a rate of 11.4% in those born to 
HIV-infected mothers [20]. Our findings confirm previous findings of a very high rate of 
congenital CMV infection in HIV-infected infants [7,10,15,19,21].
In previous studies, infant CMV infection among HIV-uninfected neonates was associated 
with maternal age, antiretroviral treatment, CD4+ cell count, plasma, and breast milk viral 
load [15,22]. In the current study, CD4+ cell count and plasma HIV viral load were found to 
be significantly associated with infant CMV infection, whereas maternal age and 
antiretroviral status were not. The BAN study, however, did not initiate antiretrovirals until 
the time of labor. High levels of CMV in breast milk of HIV-infected mothers were 
demonstrated throughout lactation, with highest levels in the first 24 weeks postpartum [22], 
which correlates with the time of postnatal infant CMV acquisition we observed.
We found no significant correlation between CMV DNAemia and severe infant morbidity or 
decreased growth. These findings are different from those of a previous study among HIV-
exposed infants [6], and may be due to the low levels of CMV observed in our study infants. 
However, our findings show that detection of CMV DNA in the blood at 24 weeks was 
associated with the combined outcome of HIVacquisition or death from 24 to 48 weeks of 
age, which is a novel finding. The mechanisms underlying this association may be through 
CMV-mediated enhancement of HIV shedding in breast milk [23]. CMV in breast milk 
could be a co-factor that influences level of mucosal shedding of HIV, even in women 
receiving HAART.
To our knowledge, our study is the first to examine the effect of maternal antiretrovirals on 
the risk of postnatal transmission of CMV. The lack of an effect suggests that initiation of 
antiretroviral therapy prenatally may be necessary in order to allow time for CMV levels in 
breast milk (or other secretions) to decrease. Alternatively, the lack of an association with 
antiretroviral therapy may be due to an overall high level of CMV exposure in this 
population, possibly not related to breastfeeding.
One limitation to our study was the use of only blood specimens for PCR detection of 
congenital CMV, as urine or saliva was not available. It is thus possible that the congenital 
CMV DNAemia rates we report are underestimates of the true congenital CMV infection 
rates. Another limitation of the study was the small number of BAN infants with available 
specimens (492/2369), which may not have been fully representative of the entire study 
population.
These limitations notwithstanding, our study has many strengths. First, we had access to 
specimens from different time points in the infant’s first year of life, allowing us to more 
closely determine timing of CMV acquisition. In addition, because of length of follow-up 
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for up to 48 weeks, we were able to incorporate data on morbidity and mortality for up to a 
year of an infant’s life.
In conclusion, our data indicate that early postnatal CMV infection in an HIV-exposed 
infant may predict subsequent HIV transmission through breastfeeding and infant mortality, 
suggesting that preventing or delaying CMV infection may offer advantages for HIV 
prevention. The role of maternal antiretroviral treatment, or of other possible adjunct 
approaches targeting CMV, in decreasing the burden of this important co-infection, need to 
be further investigated.
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Kaplan–Meier estimates of the cumulative risk of infant HIV infection or death between 24 
and 48 weeks of age by cytomegalovirus PCR result at 24 weeks.
Chang et al. Page 10

























Chang et al. Page 11
Table 1
Associations between infant cytomegalovirus PCR results at 24 weeks of age and infant morbidity/mortality 
and growth outcomes during 48 weeks of follow-up [The Breastfeeding, Antiretrovirals and Nutrition (BAN) 
Study, Lilongwe, Malawi].
CMV PCR at 24 weeks
Hazard ratio (95% CI)a P value
HIV infection (2–48 weeks) 1.99 (0.57–6.92) 0.28
HIV infection (24–48 weeks) 4.52 (0.58–35.3) 0.15
Infant death 4.05 (0.51–32.0) 0.18
HIV infection or infant death (2–48 weeks) 2.49 (0.86–7.21) 0.09
HIV infection or infant death (24–48 weeks) 4.27 (0.99–18.4) 0.05
Severe pneumonia/SFI 1.31 (0.78–2.18) 0.31
Severe diarrhea or growth faltering 0.79 (0.38–1.66) 0.54
Severe malaria 1.51 (0.47–4.84) 0.49
Mean difference in Z-score (95% CI)a P value
Weight-for-age 0.02 (−0.17–0.22) 0.81
Length-for-age 0.11 (−0.08–0.29) 0.27
CI, confidence interval; CMV, cytomegalovirus; SFI, serious febrile illness.
a
All hazard ratios and coefficients adjusted for antiretroviral treatment group.
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